Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $152,241.84 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 3,177 shares of the business’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total transaction of $152,241.84. Following the sale, the chief operating officer now directly owns 29,588 shares of the company’s stock, valued at approximately $1,417,856.96. The trade was a 9.70 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Peter Radovich also recently made the following trade(s):

• On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total value of $85,554.36.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM opened at $48.60 on Thursday. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -24.06 and a beta of 0.98. The firm has a fifty day moving average price of $44.03 and a 200 day moving average price of $41.75. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $49.58.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. The firm had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business’s quarterly revenue was up 89.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.57) earnings per share. As a group, sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on MIRM shares. HC Wainwright restated a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Robert W. Baird increased their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Citigroup lifted their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Leerink Partners upped their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Mirum Pharmaceuticals has an average rating of “Buy” and a consensus target price of $57.10.

Institutional Trading of Mirum Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Legato Capital Management LLC boosted its position in shares of Mirum Pharmaceuticals by 7.9% during the 4th quarter. Legato Capital Management LLC now owns 13,395 shares of the company’s stock valued at $554,000 after acquiring an additional 977 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at $413,000. Empowered Funds LLC bought a new position in Mirum Pharmaceuticals during the fourth quarter valued at $1,376,000. Golden State Equity Partners grew its stake in shares of Mirum Pharmaceuticals by 1,390.8% in the 4th quarter. Golden State Equity Partners now owns 19,380 shares of the company’s stock worth $801,000 after buying an additional 18,080 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Mirum Pharmaceuticals by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock worth $421,000 after buying an additional 1,003 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.